Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn’s disease and ulcerative colitis

Objective: The infliximab biosimilar CT-P13 (Remsima(®), Inflectra(®)) was approved in Europe for the treatment of inflammatory bowel disease (IBD) based on extrapolation of data from patients with rheumatic disease. Because there are limited published reports on clinical outcomes for IBD patients t...

Descripción completa

Detalles Bibliográficos
Autores principales: Keil, Radan, Wasserbauer, Martin, Zádorová, Zdena, Hajer, Jan, Drastich, Pavel, Wohl, Pavel, Beneš, Marek, Bojková, Martina, Svoboda, Pavel, Konečný, Michal, Falt, Přemysl, Vaňásek, Tomáš, Pešta, Martin, Pešek, František, Bouchner, Luděk, Koželuhová, Jana, Novotný, Aleš, Bartůsková, Lucie, Špičák, Julius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926778/
https://www.ncbi.nlm.nih.gov/pubmed/27002981
http://dx.doi.org/10.3109/00365521.2016.1149883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926778/
https://www.ncbi.nlm.nih.gov/pubmed/27002981
http://dx.doi.org/10.3109/00365521.2016.1149883

Ejemplares similares